Advertisement
UK markets close in 3 hours 33 minutes

  • FTSE 100

    8,092.83
    +52.45 (+0.65%)
     

  • FTSE 250

    19,712.94
    -6.43 (-0.03%)
     

  • AIM

    755.18
    +0.49 (+0.06%)
     

  • GBP/EUR

    1.1671
    +0.0026 (+0.22%)
     

  • GBP/USD

    1.2510
    +0.0048 (+0.38%)
     

  • Bitcoin GBP

    51,065.70
    -2,092.62 (-3.94%)
     

  • CMC Crypto 200

    1,357.75
    -24.82 (-1.80%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.95
    +0.14 (+0.17%)
     

  • GOLD FUTURES

    2,342.20
    +3.80 (+0.16%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,963.37
    -125.33 (-0.69%)
     

  • CAC 40

    8,011.29
    -80.57 (-1.00%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

AstraZeneca developing reversal agent for blood-thinner Brilinta

Reuters - UK Focus

LONDON, Nov 13 (Reuters) - AstraZeneca (NYSE: AZN - news) is developing an antibody treatment to rapidly reverse the blood-thinning effects of its heart drug Brilinta in rare emergency situations, such as urgent surgery or in the event of major bleeding.

The drugmaker said on Thursday that the experimental product, MEDI2452, was in pre-clinical tests at its MedImmune biotech unit.

There are currently no approved medicines to counteract the blood-thinning effects of drugs such as Brilinta, which work by blocking the action of platelets in the blood. (Reporting by Ben Hirschler; editing by James Davey)